Top Markets
#1 Seeker Seeker +18.80%
#2 EXOD EXOD +9.04%
#3 Wrapped Aave Ethereum WETH Wrapped Aave Ethereum WETH +7.47%
#4 Arowana Arowana +5.88%
#5 MetaDAO MetaDAO +4.67%
#6 Wrapped STX (Velar) Wrapped STX (Velar) +4.02%
#7 Mina Protocol Mina Protocol +3.88%
#8 Pons Pons +3.00%
#9 Solstice Solstice +2.88%
#10 Official Trump Official Trump +2.75%
Coin of the day
Seeker Seeker
Einstellungen
Sprache
DEUTSCH
Währung
USD
Thema
Alpine Immune Sciences, Inc. Alpine Immune Sciences, Inc.

Alpine Immune Sciences, Inc.

ALPN
Rang in Aktien #6581
Alpine Immune Sciences, Inc. is a clinical-stage biopharmaceutical company... Alpine Immune Sciences, Inc. is a clinical-stage biopharmaceutical company focused on discovering and advancing protein-based immunotherapies. Their therapeutic endeavors address a range of conditions, including various cancers, autoimmune and inflammatory disorders, among others. The company's pipeline features ALPN-101, an ICOS/CD28 antagonist program being developed for autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor aimed at treating cancer; and ALPN-303, a dual B cell cytokine antagonist for B cell-mediated inflammatory and autoimmune conditions. Alpine Immune Sciences has established strategic collaborations, including an agreement with AbbVie Ireland Unlimited Company for the development of ALPN-101, and a partnership with Adaptimmune Therapeutics plc to create next-generation SPEAR T cell products. The company was founded in 2007 and operates from its headquarters in Seattle, Washington.
Aktienkurs
$64.97
Zuletzt synchronisiert: 2024-05-20
Marktkapitalisierung
$1.97B
Veränderung (1 Tag)
0.00%
Veränderung (1 Jahr)
0.00%
Land
US
Handel Alpine Immune Sciences, Inc. (ALPN)

Kategorie

Healthcare
Gewinn für Alpine Immune Sciences, Inc. (ALPN)
Gewinn im Mar 2024 TTM: $-36.73M
Laut den aktuellen Finanzberichten von Alpine Immune Sciences, Inc. betragen die aktuellen Gewinne des Unternehmens $-36.73M. Im Jahr 2022 erzielte das Unternehmen einen Gewinn von $-55.43M, ein Rückgang im Vergleich zu dem Gewinn im Jahr 2021, der $-50.42M betrug. Die auf dieser Seite angezeigten Gewinne sind die Gewinne vor Zinsen und Steuern, auch bekannt als EBIT.
Gewinnverlauf von Alpine Immune Sciences, Inc. von 2012 bis 2026
Gewinn am Ende jedes Jahres
Jahr Gewinn ändert
2026 (TTM) $-36.73M 14.50%
2023 $-32.08M -42.13%
2022 $-55.43M 9.94%
2021 $-50.42M 80.42%
2020 $-27.95M -33.23%
2019 $-41.85M 13.56%
2018 $-36.85M 361.64%
2017 $-7.98M -74.63%
2016 $-31.46M 37.89%
2015 $-22.82M 51.76%
2014 $-15.04M -7.17%
2013 $-16.20M 69.21%
2012 $-9.57M 0.00%
Gewinn ähnlicher Unternehmen oder Konkurrenten
Unternehmen Gewinn Gewinnunterschied Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -14,460.11%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -5,410.35%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
$-4.02B 10,833.48%
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B 8,303.89%
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH